Ticagrelor Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Ticagrelor Supply and Access in 2026

Ticagrelor (Brilinta) remains a cornerstone of dual antiplatelet therapy (DAPT) for acute coronary syndrome, post-MI maintenance, and more recently, secondary stroke prevention. As generic competition matures and the supply landscape evolves, providers should be aware of the current state of Ticagrelor availability, cost dynamics, and tools that can help patients access their medications reliably.

This briefing provides a concise overview for cardiologists, internists, neurologists, emergency physicians, and other prescribers who write Ticagrelor prescriptions.

Supply Timeline: From Brand-Only to Generic Competition

Understanding the supply landscape requires context on how we got here:

• 2011: FDA approves Brilinta (ticagrelor) for ACS based on the PLATO trial
• 2020: FDA expands indication to include reduction of stroke risk in acute ischemic stroke and high-risk TIA (THALES trial)
• 2023: AstraZeneca's key patents expire; generic ticagrelor enters the U.S. market from multiple manufacturers
• 2023-2024: Transition period with intermittent supply disruptions as generic manufacturers scale production
• 2025-2026: Generic market stabilizes; multiple manufacturers producing both 60 mg and 90 mg tablets

As of early 2026, there is no FDA-listed shortage of ticagrelor. The ASHP Drug Shortage Resource Center does not currently list ticagrelor as being in shortage.

Prescribing Implications

Generic Substitution

Generic ticagrelor is rated AB-equivalent to Brilinta and can be substituted at the pharmacy level in all 50 states unless the prescriber specifies "dispense as written" (DAW). For most patients, generic substitution is appropriate and results in significant cost savings.

Dosing Reminders

Ticagrelor dosing varies by indication:

• Acute coronary syndrome: 180 mg loading dose, then 90 mg BID with aspirin 81 mg daily for up to 12 months
• Post-MI maintenance (beyond 12 months): 60 mg BID with aspirin 75-100 mg daily
• Stroke/TIA prevention: 180 mg loading dose, then 90 mg BID with aspirin 325 mg on day 1, then aspirin 75-100 mg daily for 30 days

Critical reminder: The boxed warning specifies that maintenance aspirin doses above 100 mg/day reduce ticagrelor's effectiveness. Ensure patients are not taking additional OTC aspirin-containing products.

Drug Interaction Considerations

Key interactions that affect prescribing decisions:

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): Contraindicated — substantially increases ticagrelor exposure
• Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine): Substantially decreases ticagrelor levels — avoid concomitant use
• Simvastatin/lovastatin: Ticagrelor increases exposure; limit simvastatin to 40 mg/day
• Digoxin: Monitor levels; ticagrelor may increase digoxin concentrations

For a comprehensive interaction reference, see our post on Ticagrelor drug interactions.

Current Availability Picture

While nationally the supply is adequate, providers should be aware that patients may encounter localized stock-outs. Common scenarios include:

• Chain pharmacy inventory gaps: Automated ordering systems may not stock ticagrelor at locations with low dispensing volume
• Formulary-driven switching: Some payers have shifted preferred status to clopidogrel, reducing pharmacy stocking incentives for ticagrelor
• Brand vs. generic stocking: Pharmacies that previously stocked Brilinta may not yet carry generic ticagrelor from their current wholesaler

Patients who report difficulty finding ticagrelor should be directed to Medfinder for providers, which offers real-time pharmacy stock checking and can help identify nearby pharmacies with availability.

Cost and Access Landscape

The cost picture has changed dramatically with generic entry:

• Brand Brilinta: $400-$500+/month (retail)
• Generic ticagrelor (retail, no insurance): ~$444/month
• Generic ticagrelor (with discount card): As low as $31/month
• Generic ticagrelor (insured, generic tier): $5-$30 copay/month

Insurance Coverage Patterns

Most commercial plans and Medicare Part D formularies now include generic ticagrelor as a preferred generic (Tier 1-2). Brand Brilinta typically falls on a higher tier (Tier 3) and may require prior authorization or step therapy through clopidogrel first.

For patients with coverage gaps or high deductibles, discount cards can reduce costs dramatically. Direct patients to our resource on saving money on Ticagrelor.

Patient Assistance Programs

• AstraZeneca AZ&Me Program: Free Brilinta for qualifying uninsured/underinsured patients (income-based eligibility). Apply at azandmeapp.com or 1-800-292-6363.
• Brilinta Savings Card: For commercially insured patients, copay may be reduced to as low as $18/month.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder's provider tools allow your office staff to quickly verify pharmacy stock before sending prescriptions, reducing patient callbacks and improving fill rates.

Prescribing Workflow Tips

1. Specify generic ticagrelor on prescriptions unless there's a clinical reason for brand
2. Include both 60 mg and 90 mg strengths on your e-prescribe favorites for quick access
3. Document aspirin dose in your notes and patient instructions to prevent inadvertent high-dose aspirin use
4. Proactively discuss cost — many patients don't know about discount cards and may abandon prescriptions due to sticker shock at the pharmacy

Alternative Agents

When ticagrelor is unavailable or contraindicated, consider:

• Clopidogrel 75 mg daily: First-line alternative; consider CYP2C19 testing if clinically appropriate
• Prasugrel 10 mg daily: More potent; avoid in patients with prior stroke/TIA, age >75, or weight <60 kg
• Cangrelor (IV): For periprocedural use in patients who cannot receive oral P2Y12 inhibitors

For a patient-facing comparison, refer patients to our post on alternatives to Ticagrelor.

Looking Ahead

The ticagrelor market is expected to continue stabilizing as generic competition matures. Key trends to watch:

• Price compression: Generic prices are likely to decrease further as more manufacturers enter the market
• Formulary evolution: Payers may increasingly require step therapy through clopidogrel before covering ticagrelor, even in generic form
• Expanded indications: Ongoing research into ticagrelor's role in PAD and other vascular conditions may expand the prescribing population

Final Thoughts

Ticagrelor remains a guideline-recommended agent for multiple cardiovascular and cerebrovascular indications. While supply is generally adequate in 2026, providers play a key role in helping patients navigate availability challenges, cost barriers, and formulary restrictions. Leveraging tools like Medfinder for providers and proactively discussing cost with patients can significantly improve medication adherence and outcomes.

For more clinical resources, see our provider's guide to helping patients find Ticagrelor and our guide to helping patients save money on Ticagrelor.